Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment

Hypertension Research

Volumn 35, Issue 8, 2012, Pages 862-866

  Hoshide, Satoshi ^a   Yano, Yuichiro ^a   Shimizu, Motohiro ^a   Eguchi, Kazuo ^a   Ishikawa, Joji ^a   Kario, Kazuomi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

day to day blood pressure variability; home blood pressure; urinary albumin excretion

Indexed keywords

ALBUMIN; CANDESARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; TRICHLORMETHIAZIDE;

ADD ON THERAPY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CREATININE; DIURETICS; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; TETRAZOLES; TREATMENT OUTCOME;

EID: 84864656838     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2012.46     Document Type: Article

References (23)

1. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: The Ohasama study. Hypertension 2000; 36: 901-906.
2. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, Jaaskivi M, Nachev C, Parati G, O'Brien ET, Tuomilehto J, Webster J, Bulpitt CJ, Fagard RH. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 2003; 21: 2251-2257.
3. Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, Ferrario M, Mancia G. Blood pressure variability and organ damage in a general population: results from the PAMELA study. Hypertension 2002; 39: 710-714.
4. Kikuya M, Ohkubo T, Metoki H, Asayama K, Hara A, Obara T, Inoue R, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: The Ohasama study. Hypertension 2008; 52: 1045-1050.
5. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895-905.
6. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Telera MP, Pede S, Gattobigio R, Porcellati C. Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. J Hypertens 1998; 16: 1335-1343.
7. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G, De Caterina R. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension 2007; 50: 325-332.
8. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for carotid artery measures in the elderly at high risk of cardiovascular disease. J Am Soc Hypertens 2011; 5: 184-192.
9. Matsui Y, Ishikawa J, Eguchi K, Shibasaki S, Shimada K, Kario K. Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension 2011; 57: 1087-1093.
10. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198-202.
11. Araki S, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, Isshiki K Chin-Kanasaki M, Uzu T, Kashiwagi A. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007; 56: 1727-1730.
12. Maisel AS. Cardiovascular and renal surrogate markers in the clinical management of hypertension. Cardiovasc Drugs Ther 2009; 23: 317-326.
13. Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, Ishikawa S, Shimada K. Effect of dosing time of angiotensin ii receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: The Japan morning surge-target organ protection (J-TOP) study. J Hypertens 2010; 28: 1574-1583.
14. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H. The Japanese Society of Hypertension Guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
15. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Poulter NR Sever PS. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010; 9: 469-480.
16. Stergiou GS, Parati G. How to best assess blood pressure?: the ongoing debate on the clinical value of blood pressure average and variability. Hypertension 2011; 57: 1041-1042.
17. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Factors affecting the variability of home-measured blood pressure and heart rate: The Finn-home study. J Hypertens 2010; 28: 1836-1845.
18. Matsui Y, Eguchi K, Shibasaki S, Shimizu M, Ishikawa J, Shimada K, Kario K. Association between the morning-evening difference in home blood pressure and cardiac damage in untreated hypertensive patients. J Hypertens 2009; 27: 712-720.
19. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, Murata M, Kuroda T, Schwartz JE, Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401-1406.
20. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499.
21. Lattanzio MR, Weir MR. Have we fallen off target with concerns surrounding dual raas blockade? Kidney Int 2010; 78: 539-545.
22. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181.
23. Ushigome E, Fukui M, Hamaguchi M, Senmaru T, Sakabe K, Tanaka M, Yamazaki M, Hasegawa G, Nakamura N. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res 2011; 34: 1271-1275.